Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Alcorn

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
BMJ (Clinical Research Ed.)|August 2, 2019
HIV in 2019: it's all about dolutegravirKeith Alcorn
IAPAC Monthly|March 24, 2007
TMC125 study highlights failing NNRTI regimen taskKeith Alcorn
IAPAC Monthly|April 2, 2005
Is PEPFAR tackling HIV drug supply in wrong way?Keith Alcorn
IAPAC Monthly|April 28, 2004
400 percent ritonavir price hikeKeith Alcorn
IAPAC Monthly|April 28, 2004
Abbott announces RTV price concessionsKeith Alcorn
IAPAC Monthly|April 28, 2004
Resistance: what are the implications for treatment?Keith Alcorn
IAPAC Monthly|May 26, 2007
Delaying maternal NVP-based ART more effectiveKeith Alcorn
IAPAC Monthly|October 24, 2007
Mixed co-receptor use associated with lower CD4 countKelly Morris, Keith Alcorn
IAPAC Monthly|March 30, 2007
After Toronto, 46th ICAAC offers back to basicsKeith Alcorn, Edwin J Bernard, Michael Carter, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 6, 2003
Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signalingValerie I Brown, Junjie Fang, Keith Alcorn, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
BMJ (Clinical Research Ed.)|August 2, 2019
HIV in 2019: it's all about dolutegravirKeith Alcorn
IAPAC Monthly|March 24, 2007
TMC125 study highlights failing NNRTI regimen taskKeith Alcorn
IAPAC Monthly|April 2, 2005
Is PEPFAR tackling HIV drug supply in wrong way?Keith Alcorn
IAPAC Monthly|April 28, 2004
400 percent ritonavir price hikeKeith Alcorn
IAPAC Monthly|April 28, 2004
Abbott announces RTV price concessionsKeith Alcorn
IAPAC Monthly|April 28, 2004
Resistance: what are the implications for treatment?Keith Alcorn
IAPAC Monthly|May 26, 2007
Delaying maternal NVP-based ART more effectiveKeith Alcorn
IAPAC Monthly|October 24, 2007
Mixed co-receptor use associated with lower CD4 countKelly Morris, Keith Alcorn
IAPAC Monthly|March 30, 2007
After Toronto, 46th ICAAC offers back to basicsKeith Alcorn, Edwin J Bernard, Michael Carter, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 6, 2003
Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signalingValerie I Brown, Junjie Fang, Keith Alcorn, et al.
Pageof 2